ArticleCurrent microbiology2025
Comamonas resistens Co-Producing GES-5 and OXA-17 in Urban Wastewater as a Potential Novel Disseminator of Clinically Relevant β-Lactamases.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Coupling continuous directed evolution with base editors identifies combinatorial antibiotic resistance.Biotechnology letters · 2026Article
- Genomic characterization of carbapenemase-producing Enterobacterales from wastewater reveals the convergence of KPC-2 and GES-16 in Brazil.Environmental monitoring and assessment · 2026Article
- First Report of a Carbapenem-ResistantInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Comamonas species have been isolated from different sources, with Comamonas testosteroni and Comamonas resistens commonly related to human diseases and multidrug resistance, respectively. During a surveillance study to monitor carbapenem resistance in bacteria from wastewater samples in Brazil, a carbapenem-resistant strain, named M13, was obtained and identified as C. resistens (ANI 98.90%, dDDH 94.60%) by genomic analysis, being a species distinct from C. testosteroni. It exhibited multidrug resistance and presented small inhibition zones around disks containing novel β-lactams and β-lactam-β-lactamase inhibitor combinations. Comparative genomics showed significant single nucleotide polymorphism divergence between M13 and other C. resistens genomes, suggesting geographically driven genomic diversity. Strain M13 uniquely harbored genes related to antimicrobial resistance and metal tolerance as follows: bla
Indexed as
Identifiers
40719913What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.